BACKGROUND: For patients who have acute promyelocytic leukemia (APL) in second complete remission (CR2), optimal postremission strategies remain undefined. METHODS: The role of an oral arsenic trioxide (As 2 O 3 )-based regimen in the management of patients who had APL in CR2 was examined. RESULTS: Seventy-three patients with APL in first relapse (R1) were studied. Oral As 2 O 3 -based reinduction resulted uniformly in CR2, irrespective of previous As 2 O 3 exposure. All patients received oral As 2 O 3 -based maintenance in CR2. At a median follow-up of 94 months (range, 9-205 months), 43 patients (58.9%) were still in CR2, and 49 (67.1%) had finished the planned 2-year CR2 maintenance with all-trans retinoic acid, oral As 2 O 3 , and ascorbic acid. Reinduction and maintenance treatments were well tolerated. Grade 1 and 2 headache occurred in 20 patients (27.4%). Hepatotoxicity, all in the form of transaminitis, occurred in 35 patients (47.9%; grade 1 and 2, n 5 26; grade 3 and 4, n 5 9). Three patients had self-limiting QTc prolongation. The 10-year leukemia-free survival rate was 56.8%. Thirty patients developed R2. Oral As 2 O 3 -based reinduction led to CR3 in 27 patients (90%). Post-CR3 strategies included autologous hematopoietic stem cell transplantation and oral As 2 O 3 maintenance. At a post-CR3 follow-up of 30 months (range, 3-166 months), 11 patients were still in CR3. The 5-year and 10-year overall survival rates in the R1 cohort were 79.5% and 67.3%, respectively. Prior receipt of oral As 2 O 3 maintenance in CR1 was the only risk factor for inferior leukemia-free survival. Central nervous system involvement occurred in 15 patients, including 5 who remained alive. Relapse during oral As 2 O 3 therapy was the only significant risk factor for central nervous system involvement. CONCLUSIONS: For patients with relapsed APL, As 2 O 3 remained effective despite repeated As 2 O 3 exposures. Oral As 2 O 3 maintenance was an effective postremission strategy for CR2. Cancer 2018;124:2316-26. V C 2018 American Cancer Society.
INTRODUCTION
Acute promyelocytic leukemia (APL) is characterized by the translocation t(15;17)(q24;21) and the fusion gene promyelocytic leukemia/retinoic acid receptor a (PML-RARA). 1 Optimal supportive care with the use of all-trans retinoic acid (ATRA) and chemotherapy has resulted in first complete remission (CR1) rates >90% and long-term survival rates of approximately 80%. [2] [3] [4] [5] Nevertheless, relapses occur in up 20% of patients. [2] [3] [4] [5] Arsenic trioxide (As 2 O 3 ) delivered intravenously (intravenous As 2 O 3 ) is highly efficacious for APL in first relapse (R1), inducing second complete remission (CR2) in >90% of patients. 6, 7 Similar to other acute myeloid leukemias, consolidation of CR2 with autologous or allogeneic hematopoietic stem cell transplantation (HSCT) is then recommended. 1 However, prospective data validating HSCT or other approaches as the optimal postremission therapy for APL in CR2 are not available.
Since the introduction of ATRA, extramedullary relapse of APL has increasingly been reported, 8 with the central nervous system (CNS) the most common site involved. Patients who have APL with a CNS relapse have a dismal prognosis. 9 Therefore, the prevention of and optimal treatment for CNS relapse are important facets in the management of APL.
We have formulated an oral preparation of As 2 O 3 (oral As 2 O 3 ) and have demonstrated that it is equally efficacious for APL in R1, inducing CR2 in >90% of patients. 10, 11 Furthermore, in an effort to prevent relapse, we have moved oral As 2 O 3 forward to the maintenance of CR1. This strategy results in favorable overall survival (OS) and leukemia-free survival (LFS), 11 suggesting that prolonged treatment with oral As 2 O 3 may prevent relapses.
Current protocols have incorporated intravenous As 2 O 3 into the treatment of newly diagnosed APL. [12] [13] [14] [15] [16] Patients may receive intravenous As 2 O 3 as frontline treatment for induction and/or consolidation. When relapse occurs in these As 2 O 3 -exposed patients, the disease pattern and outcome remain undefined. More crucially, it has not been determined whether As 2 O 3 may still be effective in patients with relapsed APL who have had prior exposure to frontline As 2 O 3 .
Since 2002, we have prospectively treated patients with APL in R1 using protocols that incorporate oral As 2 O 3 reinduction followed by As 2 O 3 maintenance. This R1 cohort was analyzed in the current study to address several key issues. First, we investigated the impact of prior As 2 O 3 exposure (in the form of CR1 maintenance) on the outcome of As 2 O 3 salvage during relapse. Second, the efficacy of oral As 2 O 3 maintenance as a postremission strategy for patients with an R1 in CR2 was examined. Third, because we previously demonstrated that As 2 O 3 penetrated the blood-brain barrier, 17 we also studied whether prolonged oral As 2 O 3 treatment might be useful in treating and preventing CNS relapse.
MATERIALS AND METHODS

Patients
This study included only adult patients aged >18 years. APL was diagnosed according to standard morphologic, cytogenetic, and molecular criteria. The induction regimen for newly diagnosed patients was ATRA (45 mg/m 2 daily from day 1 to CR1) plus daunorubicin (50 mg/m 2 daily for 3 days). Patients who had a leukocyte count at presentation or a peak leukocyte count during treatment of >10 3 10 9 /L received CNS prophylaxis at CR1, comprising 4 doses of intrathecal methotrexate (12 mg weekly) and cytarabine (50 mg weekly). Consolidation comprised daunorubicin (50 mg/m 2 daily for 2 days) and cytarabine (100 mg/m 2 daily for 5 days) given monthly for 2 cycles. Maintenance comprised oral As 2 O 3 -based regimens in our center 18 and ATRA-based regimens in other centers. 18 All patients provided informed consent to treatment. The use of oral As 2 O 3 has been approved by the Institutional Review Board of the University of Hong Kong.
Recruitment of Patients in R1
In Hong Kong, our institute is the only center at which As 2 O 3 (intravenous or oral) is available. We have used exclusively oral As 2 O 3 . Therefore, every patient with relapsed APL in Hong Kong is referred to and treated by us. Thus, the cohort of patients in R1 reported here represented all consecutive, unselected cases.
Treatment of R1 and CNS Prophylaxis at CR2
For patients in R1, reinduction therapy comprised oral As 2 O 3 (10 mg daily), ATRA (45 mg/m 2 daily), and ascorbic acid (1 g daily) (AAA) on days 1 through 28 18 and idarubicin (6 mg/m 2 daily for 5 days). On achieving CR2, patients received 2 monthly cycles of consolidation with idarubicin (6 mg/m 2 daily for 2 days). 19 All patients who achieved CR2 received CNS prophylaxis (4 doses of intrathecal methotrexate and cytarabine). On completion of consolidation, patients received maintenance with the AAA regimen (2 weeks every 2 months for 2 years per protocol). 18 
Treatment of CNS Involvement at R1
Patients who had CNS involvement at R1 received treatment with twice-weekly intrathecal methotrexate and cytarabine until clearance of cerebrospinal fluid (CSF), followed by 2 additional weekly doses. Systemic treatment with AAA and reinduction chemotherapy similar to that for bone marrow R1, irrespective of whether it had actually occurred concomitantly, also was instituted. Postremission, patients received consolidation with craniospinal irradiation followed by AAA maintenance for 2 years.
Treatment of R2 or More Advanced Relapses
For R2, reinduction therapy comprised AAA, mediumdose cytarabine (500 mg/m 2 daily on days 1-5), and mitoxantrone (12 mg/m 2 daily on days 2-4). For R3 or more advanced relapses, reinduction therapy comprised AAA with or without systemic chemotherapy, with the choice of regimen (gemtuzumab ozogamicin, doxorubicin, epirubicin) at the discretion of the attending physician.
Treatment of CNS Involvement at R2 or More Advanced Relapses
The treatment was the same as that for patients who had CNS involvement at R1, comprising intrathecal methotrexate and cytarabine plus systemic therapy with AAA and reinduction chemotherapy similar to that for bone marrow R2 and beyond. Craniospinal irradiation was given to patients who had not previously received it.
Toxicity Assessment
Treatment toxicity during reinduction and maintenance was defined using the Eastern Cooperative Oncology Group Common Toxicity Criteria.
Molecular Monitoring
Reverse transcription-polymerase chain reaction (RT-PCR) analysis for the PML-RARA fusion transcript was performed as previously described 19 on all bone marrow samples, which typically were obtained at relapse and for confirmation of remission after reinduction. Thereafter, peripheral blood was tested every 3 months during 2 years of maintenance. Subsequently, RT-PCR was performed every 4 to 6 months. Molecular relapse was defined as 2 consecutive positive results 2 weeks apart. A bone marrow aspirate was obtained at the time of molecular relapse to define whether there also was morphologic relapse. Fmslike tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) and tyrosine kinase domain mutations were determined at diagnosis.
Hematopoietic Stem Cell Transplantation
HSCT was not recommended for patients in R1 during CR2 based on the proposition that oral As 2 O 3 maintenance might obviate this need. Autologous HSCT was recommended for all patients in R2 during CR3 who had undetectable PML-RARA (in bone marrow and peripheral blood). Allogeneic HSCT was only recommended for patients who relapsed after autologous HSCT. The age limits for autologous and allogeneic HSCT were 65 and 60 years, respectively.
Risk Factor Evaluation
To evaluate the impact of continuous variables on prognosis, the receiver operating curve method was used to assess optimal cutoff values. Briefly, for each continuous variable, an area-under-the-curve analysis was used to determine the cutoff value with the best sensitivity and specificity for outcome. The impact of known prognostic indicators also was examined in our R1 cohort. Two groups of data were examined: initial presentation parameters when patients were newly diagnosed and parameters at R1. Initial presentation parameters that were examined included sex, age (>40 vs 40 years), pathologic subtypes (classical vs microgranular variant; therapy-related vs de novo), the presence of additional karyotypic abnormalities, molecular features (PML-RARA breakpoint cluster 1 [bcr1] vs bcr3 isoforms; FLT3-ITD vs wild-type FLT3), 9 /L), and the presence of APL differentiation syndrome during reinduction. Antecedent relapse during oral As 2 O 3 therapy versus relapse after the completion of oral As 2 O 3 therapy was evaluated as a risk factor for CNS involvement at a subsequent relapse.
Definitions and Statistical Analyses
Data were censored on September 30, 2017. OS was measured from start of oral As 2 O 3 -based reinduction at R1 to death (event) or last follow-up (censored). LFS for patients in CR2 was measured from CR2 to R2 (event) or last follow-up (censored). Therefore, LFS in this study reflected the effects of our regimens used at R1. Categorical variables were analyzed with the chi-square test, and continuous variables were analyzed using the MannWhitney U test. Univariate analyses of prognostic factors for R2 and CNS involvement were performed with logistic regression. Survival analyses were performed using the Kaplan-Meier method, with differences between groups determined using the log-rank test and a Cox proportionalhazard model. Factors with P values < .1 on univariate analysis were included in the multivariate analysis. Twotailed P values < .05 were regarded as significant. All statistical analyses were performed with the SPSS software package (version 23.0; SPSS Inc, Chicago, IL).
RESULTS
Patients in R1
In the 15-year period from January 1, 2002 to September 31, 2017, 73 patients with APL (42 men and 31 women) relapsed (Table 1) (Fig. 1 ). CNS involvement in R1 occurred in 2 (3%) of these patients (isolated, n 5 1; concomitant bone marrow relapse, n 5 1). Every patient received treatment without exclusion. The median patient age was 43 years (age range, 21-78 years), and 5 patients were aged >65 years. Relapse occurred at a median of 24 months (range, 4-245 months) from CR1. Maintenance therapy during CR1 was absent in 30 patients, ATRAbased therapy was used in 28 patients, and oral As 2 O 3 -based therapy was used in 15 patients. There was no 
Treatment and Outcome of Patients in R1
Reinduction with AAA led to CR2 in all patients, irrespective of previous As 2 O 3 exposure in the form of CR1 maintenance. All patients achieved negative RT-PCR results for the PML-RARA fusion transcript at day 28 after reinduction. At a median follow-up of 94 months (range, 9-205 months), 42 patients (57.5%) were still in CR2 (Fig. 1) , and 49 (67.1%) had finished the planned 2-year CR2 AAA maintenance. Reinduction and maintenance treatment was well tolerated ( Table 2) . Grade 1 and 2 headache occurred in 20 patients (27.4%). Hepatotoxicity, all in the form of transaminitis, occurred in 35 patients (47.9%; grade 1 and 2, n 5 26; grade 3 and 4, n 5 9). In the 26 patients who had grade 1 and 2 hepatotoxicity, dose reduction/interruption was not required. In the 9 patients who had grade 3 hepatotoxicity, oral As 2 O 3 was withheld until the alanine aminotransferase level was less than 2.5 times the upper limit of normal and was resumed at 5 mg twice daily thereafter. Prolonged QTc interval occurred in 3 patients, only 1 of whom required a transient dose interruption. None of the patients had arrhythmia or impaired cardiac function after treatment. Abbreviations: 6, with or without; 6-MP, oral 6-mercaptopurine; APL, acute promyelocytic leukemia; As 2 O 3 , arsenic trioxide; ATRA, all-trans retinoic acid; bcr, breakpoint cluster region; CNS, central nervous system; CR1, first complete remission; FLT3, Fms-like tyrosine kinase 3; ITD, internal tandem duplication; MTX, methotrexate; PML-RARA, promyelocytic leukemia/retinoic acid receptor a; WT, wild type.
Prognostic Factors for LFS After CR2
The 3-year, 5-year, and 10-year LFS rates after CR2 were 63.1%, 56.8%, and 56.8%, respectively ( Fig. 2A) . Clinicopathologic parameters at initial diagnosis and at R1 were evaluated for their impact on LFS after CR2 (Table  3, Supporting Table 1 ). On univariate analysis, the presence of FLT3-ITD (P 5 .03), oral As 2 O 3 -based maintenance at CR1 (P 5 .03), and a time to R1 24 months (P 5 .02) were associated with inferior LFS (Fig.  2B-D) . Patients who had APL with the short PML-RARA isoform (bcr3) had a trend toward inferior LFS (P 5 .07).
The 10-year LFS of patients who relapsed >24 months from CR1 was 69.4%, whereas that of patients who relapsed 24 months was only 44.4%. On multivariate analysis, oral As 2 O 3 -based maintenance at the time of CR1 was associated with inferior LFS (P 5 .007). A time to R1 24 months had only a trend (P 5 .06) toward inferior LFS.
Patients in R2
Thirty patients (21 men and 9 women) developed R2 at a median of 19 months (range, 3-51 months) from CR2. CNS involvement occurred in 9 (30%) of these patients (isolated, n 5 4; concomitant bone marrow relapse, n 5 5). None of these 9 patients had CNS involvement during R1.
Risk Factors for R2
On univariate analysis, a time to R1 of 24 months (P 5 .02) was associated with a higher risk of R2. Male gender (P 5 .08) and the presence of FLT3-ITD (P 5 .06) had a trend toward a higher risk of R2 (Supporting Table 2 ). On multivariate analysis, a time to R1 24 months had only a trend (P 5 .06) toward a higher risk of R2.
Treatment and Outcome of Patients in R2
Oral As 2 O 3 -based reinduction regimens were administered to all patients who had an R2 (Fig. 3) . One patient died from intracerebral hemorrhage before response could be evaluated. One patient aged 76 years died from hospital-acquired pneumonia before response assessment. One patient died of refractory leukemia. Twenty-seven patients (90%) achieved CR3 (Figs. 1 and 3 ).
Long-Term Outcome of Patients in R2 who Achieved CR3
Post-CR3 strategies included continued oral As 2 O 3 maintenance (n 5 18) and autologous HSCT (n 5 9). One patient died of an unrelated cause while still in CR3. Eleven patients (40.7%) had remained in CR3 after a median follow-up of 30 months (range, 3-166 months). Sixteen patients (59.2%) had a third relapse (R3) (Fig. 3 ), of whom 3 had CNS involvement (isolated, n 5 2; concomitant bone marrow relapse, n 5 1) (Fig. 1) . Oral As 2 O 3 -based reinduction regimen in R3 still resulted in CR4 in 12 (75%) of these patients (Figs. 1 and 3 ). Three As 2 O 3 -treated patients (21%) were refractory. Ten patients in CR4 subsequently relapsed. Oral As 2 O 3 -based reinduction in fourth relapse (R4) led to CR5 in 5 (50%) of these patients. One patient has remained in CR5 for 34 months and died from severe community-acquired pneumonia. Hence, 11 of 30 (36.7%) of the patients in R2 remained alive.
Prognostic Factors for OS From R1
The 5-year and 10-year OS rates for the whole R1 cohort were 79.5% and 67.3%, respectively (Fig. 2E) . Prognostic factors for OS were determined. On univariate analysis, age >40 years at diagnosis (P 5 .07), the presence of FLT3-ITD (P 5 .09), and a time to R1 24 months (P 5 .06) trended toward inferior OS (Table 3 , Supporting Table 3 ). On multivariate analysis, age >40 years (P 5 .06) only had a trend toward inferior OS. The 10-year OS rate among patients who relapsed >24 months from CR1 was 79.5%, whereas that among those who relapsed 24 months from CR1 was only 54.7%.
CNS Involvement at Relapse
For the entire cohort, 15 patients (20.5%) had CNS involvement (isolated, n 5 8; concomitant bone marrow relapse, n 5 7) at some point in their clinical course (Fig. 1) . (Fig. 1) , 1 of whom underwent autologous HSCT.
Risk Factors for CNS Involvement
Patients who had R2 or more advanced relapses had significantly inferior OS compared with those in long-term CR2 (P < .001) (Fig. 2F) , and those who had CNS involvement at R2 and beyond had the worst prognosis. Clinicopathologic features at initial presentation and at R1 were used to predict CNS relapse at R2 or beyond (Supporting Table 5 ). On univariate analysis, relapse during prior oral As 2 O 3 -based therapy was significantly associated with a higher risk of CNS relapse at R2 or beyond (P 5 .001). A leukocyte count at R1 >10 3 10 9 /L (P 5 .06) and a peak leukocyte count at R1 >10 3 10 9 /L (P 5 .05) trended toward a higher risk of CNS relapse at R2 or beyond. On multivariate analysis, relapse during prior oral As 2 O 3 -based therapy still remained significant (P 5 .0004).
Impact of HSCT at R2
Ten patients underwent autologous HSCT (CR3, n 5 8; CR4, n 5 1; CR5, n 5 1). Although we recommended HSCT for R2 patients in CR3, not every patient accepted the option. For patients who relapsed beyond R1, the 5-year and 10-year OS rates were 55.2% and 29.7%, respectively. To evaluate the impact of HSCT performed at CR3, we compared the survival of 8 patients who underwent autologous HSCT with that of 18 patients who did not. Those who underwent autologous HSCT at CR3 had a trend toward superior OS (median survival for autologous HSCT vs no autologous HSCT: not reached vs 45 months, respectively; P 5 .06; hazard ratio, 0.35; 95% confidence interval, 0.12-1.06).
DISCUSSION
The receipt of an oral As 2 O 3 -based reinduction regimen resulted in CR2 uniformly among patients in R1, irrespective of their previous exposure to oral As 2 O 3 as CR1 maintenance. Of the patients who also developed R2, all of whom had received oral As 2 O 3 as CR2 maintenance, only 2 (6.7%) were refractory to arsenic reinduction. These results indicate that arsenic resistance during reinduction is not a serious clinical problem for patients in R1 and R2, despite previous As 2 O 3 exposure. However, in R3 and R4, As 2 O 3 refractoriness during reinduction developed in 25% and 50% of patients, respectively. Hence, arsenic resistance will only develop upon repeated and multiple administration of As 2 O 3 .
For patients who have R1 in CR2 after As 2 O 3 reinduction, the optimal postremission strategy has not been defined. Prevailing recommendations are based on retrospective analyses of highly selected patients. 1 Previous studies indicated that patients in CR2 had poor long-term relapse-free survival rates of only 22% to 37%. 6, 20, 21 HSCT is conventionally regarded as a consolidation strategy.
In the pre-As 2 O 3 era, autologous HSCT in CR2 resulted in relapse rates of 18% to 54%, LFS rates of 31% to 69%, and OS rates of 40% to 76% (Supporting Table  6 , with full list of references). Allogeneic HSCT appeared to be worse, with therapy-related mortality (TRM) rates from 17% to 40%, relapse rates from 8% to 64%, LFS rates from 22% to 59%, and OS rates from 46% to 52% (Supporting Table 6 ). A recent registry study demonstrated that autologous HSCT was superior to allogeneic HSCT in terms of OS because of a lower TRM. 22 In a report that compared chemotherapy, allogeneic HSCT, and autologous HSCT, there were no differences in 7-year OS (range, 40%-86%). Another retrospective study indicated that autologous HSCT, allogeneic HSCT, and other regimens resulted in comparable 5-year OS and relapse rates (range, 51%-58%).
In the post-As 2 O 3 era, few studies addressed the optimal post-CR2 strategy. In 35 patients who had an As 2 O 3 -induced CR2, 23 patients underwent autologous HSCT. The 5-year failure-free-survival and OS rates were 59% and 77%, respectively, for those who underwent transplantation, but were significantly worse on an intention-to-treat basis (Supporting Table 6 ). Another study evaluated allogeneic HSCT in 15 patients who had APL in CR2 (6 induced by As 2 O 3 ). The 4-year OS and relapse rates were 62% and 32%, respectively. Although the results of allogeneic HSCT conceivably might be improved with reduced-intensity conditioning, actual data on this approach are not available.
In the current study, all patients in CR2 received treatment with oral As 2 O 3 maintenance. Autologous HSCT was reserved for patients who developed R2. The LFS plateaued after 4 years at 56.8%, suggesting that these CR2 patients were potentially cured. Because oral As 2 O 3 remained effective in R2 and salvage was still feasible, the 5-year and 10-year OS rates were 79.5% and 67.3%, respectively. It is noteworthy that approximately 40% of patients who developed R2 were still living. Hence, oral As 2 O 3 maintenance regimen is an effective postremission strategy for CR2, with outcomes at least comparable to those attained with HSCT, which would have involved highly selected, good-risk patients. The short-term risk (TRM) and long-term sequelae (sterility, menopause, secondary cancers) of HSCT are obviated by our strategy. It is the best approach for patients who are ineligible for transplantation.
One of the most significant adverse factors for LFS and OS on univariate analysis was a time to R1 24 months from CR1. In fact, for patients who relapsed >24 months after CR1, the 5-year LFS was close to 70%, and the 5-year OS was greater than 90%. For patients who relapsed 24 months after CR1, the quick relapse suggests that biologic factors increasing leukemia aggressiveness may be present. Prior oral As 2 O 3 -based maintenance was the most significant predictor of worse LFS after CR2 on multivariate analysis, indicating that prior, prolonged As 2 O 3 and ATRA exposure might promote treatment resistance and relapse.
In our cohort, the leukocyte count at initial presentation or during relapse was not associated with inferior OS or LFS. A presentation leukocyte count >10 3 10 9 /L is considered a poor prognostic indicator in patients who receive treatment with ATRA and chemotherapy. 1 Our data indicated that conventional prognostic indicators and risk scores did not have an impact on patients with relapsed APL who received oral As 2 O 3 -based reinduction. Additional karyotypic aberrations at R1 did not impact on the response to As 2 O 3 . However, because karyotyping is not routinely performed for subsequent relapses, it is unclear whether additional cytogenetic aberrations might be prognostic. The presence of FLT3-ITD was associated with worse LFS after CR2 in our cohort. FLT3-ITD is observed in up to 40% of patients with APL at diagnosis and is associated with a high leukocyte count, microgranular variant, and the short PML-RARA (bcr3) isoform. [23] [24] [25] [26] With frontline ATRA and chemotherapy, FLT3-ITD is associated with worse disease-free survival and OS. 24, 25 Extramedullary relapses in the CNS have been reported in patients who have FLT3-ITD-positive APL. 27, 28 However, the impact of FLT3-ITD on patients with APL who receive treatment with As 2 O 3 , either as frontline or salvage therapy, is undefined.
In the post-ATRA era, 29 CNS relapse has become an important problem, occurring in 1.1% to 3.2% of patients. 9, 30 Risk factors that predispose patients to isolated CNS involvement at R1 include CNS hemorrhage, a presentation leukocyte count >10 3 10 9 /L, APL differentiation syndrome, microgranular variant, and the short isoform of PML-RARA. 22, 31, 32 In this study, our concern instead was to identify patients who might have CNS involvement at R2 and beyond, because this group had the worst OS in our R1 cohort. Antecedent relapse that occurred during oral As 2 O 3 therapy was the only risk factor predicting CNS involvement at a subsequent relapse. It may be possible that leukemic cells relapsing during As 2 O 3 therapy were intrinsically resistant, and CNS relapse was only 1 of the clinical manifestations. Alternatively, oral As 2 O 3 was not effective in preventing CNS leukemic relapse. We previously demonstrated that the CSF arsenic concentration was about 18% of that of plasma. 33 Although intravenous As 2 O 3 theoretically may achieve a higher CSF arsenic concentration, 34, 35 prolonged intravenous As 2 O 3 therapy is not feasible. Other strategies might increase CSF arsenic concentration, 36 but their clinical utility is limited. Hence, the most practical strategy still may be to identify at-risk patients and adopt preventive measures.
How do our results fit into the present clinical use of As 2 O 3 in APL? Currently, not every patient with newly diagnosed APL is exposed to As 2 O 3 . Hence, among patients in R1 who are naive to As 2 O 3 , a significant proportion will remain in durable CR2 after reinduction and maintenance with As 2 O 3. For patients who relapse >24 months from CR1, our strategy resulted in a remarkable 5-year OS rate of 90.8%, clearly indicating that additional therapy, including HSCT, would not be necessary. However, patients who have R1 within 24 months of CR1 are at high risk of future relapses despite As 2 O 3 maintenance, with a 5-year OS rate of only 68.6%, suggesting that additional strategies may be indicated. For patients in R1 who have had previous exposure to As 2 O 3 as either upfront induction, consolidation, or maintenance, 13, 14, 37 As 2 O 3 reinduction is still highly effective. However, patients who relapse during As 2 O 3 therapy have a high risk of CNS relapse and hence an inferior prognosis. For patients in R2 who, with current standard treatment protocols, will have been exposed to As 2 O 3 in R1, As 2 O 3 reinduction remains highly effective, but a durable CR3 with As 2 O 3 maintenance occurs in only 20% of patients. For high-risk patients in all of these respective groups, therapy in addition to As 2 O 3 maintenance is needed. It remains to be determined whether HSCT in these high-risk patients
